Arcutis Biotherapeutics Q1 2024 Adj EPS $0.32 Beats $(0.73) Estimate, Sales $49.57M Beat $14.68M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcutis Biotherapeutics (ARQT) reported Q1 2024 earnings of $0.32 per share, surpassing the $(0.73) estimate, with sales of $49.57M beating the $14.68M estimate, marking a 1.68K% increase from the previous year.
May 14, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcutis Biotherapeutics significantly exceeded Q1 2024 earnings and sales estimates, showcasing a substantial year-over-year growth.
The substantial beat on both earnings per share (EPS) and sales estimates for Q1 2024, along with a significant year-over-year sales increase, suggests a strong financial performance by Arcutis Biotherapeutics. This outperformance is likely to positively impact investor sentiment and could lead to a short-term increase in ARQT's stock price.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100